← Back to Clinical Trials
Recruiting NCT07075445

Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Long QT Syndrome Type 3
Sponsor Thryv Therapeutics, Inc.
Study Type OBSERVATIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-10-27
Completion 2026-12-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a cross-sectional observational study designed to assess the disease burden and quality of life in individuals with LQTS 2 and 3. Each participant will answer each patient-reported outcome questionnaire only once over a 6-month period. The study will enroll up to 200 participants.

Eligibility Criteria

Inclusion Criteria: 1. The participant is willing and provides written informed consent to participate in this study. 2. Male or female participant of at least 18 years of age, English-speaking. 3. Confirmed genetic diagnosis of LQT2 or 3, demonstrated by one of the following: * Genetic testing report (pathogenic or likely pathogenic (P/LP) mutation) in KCHN2 or SCN5a genes) or, * A signed physician's letter confirming genetic diagnosis of LQTS 2 or 3. 4. Documented QTc ≥ 480 ms within the last year, demonstrated by one of the following: * 12-lead electrocardiogram (ECG), or * A signed physician's letter confirming an ECG demonstrating QTc value ≥ 480 ms. 5. The participant is able to operate a smartphone and a companion watch. \*The number of participants with QTc between 480 and 500 ms will be limited to 50. Exclusion Criteria: 1. Current participation in another clinical trial involving a drug or device. 2. Participants unwilling to use an iPhone or Apple Watch for the duration of t

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}